3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Mantle-Cell
5
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, B-Cell
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Burkitt Lymphoma
1
Advanced Haematological Malignancies
1
Interventions
Gemcitabine
358
Fluorouracil
94
Oxaliplatin
81
Capecitabine
74
130-nm albumin-bound paclitaxel
71
Albumin-Bound Paclitaxel
70
Radiotherapy
67
Leucovorin
58
Irinotecan
49
Erlotinib Hydrochloride
47
Cisplatin
44
Bevacizumab
31
pembrolizumab
30
Radiosurgery
30
Docetaxel
26
Taxes
24
Nivolumab
24
Cetuximab
24
Pancreaticoduodenectomy
20
Drug Therapy
17
folfirinox
16
Cyclophosphamide
16
Radiation
15
Ipilimumab
13
Endoscopic Ultrasound-Guided Fine Needle Aspiration
13
Surgical Procedures, Operative
12
Sorafenib
12
Paclitaxel
12
Neoadjuvant Therapy
12
irinotecan sucrosofate
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Pancreatic Neoplasms
×
acalabrutinib
×
Clear all
NCT02362048
2019-10-01
KEYNOTE144
Acerta Pharma BV
Phase 2
Completed
77 enrolled
11 charts